Autres langues Biosergen AB

Actions

BIOSGN

SE0026821852

Recherche biotechnologique et médicale

Temps Différé Nasdaq Stockholm Autres places de cotation 11:19:06 21/04/2026			Varia. 5j.	Varia. 1 janv.
9,750 ^SEK	-0,51%		+2,63%	-75,33%

05/04	Biosergen envisage la cession de son candidat-médicament antifongique face à des difficultés de financement	MT
04/04	Biosergen suspend le développement du Bsg005	RE

Autres langues

08/04	Biosergen halts BSG005 development
05/04	Biosergen to Potentially Sell Antifungal Drug Candidate Amid Funding Challenges
04/04	Biosergen pauses development of Bsg005
04/04	Biosergen Pauses Development of BSG005
04/04	Biosergen AB Pauses Development of BSG005
10/02	Biosergen AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
10/02	Biosergen publishes interim report for the fourth quarter 2025
20/11	Biosergen resolved record date for reverse split
20/11	Determination of Record Date for Reverse Share Split in Biosergen
19/11	Biosergen comments on continued progress in the third quarter
19/11	Biosergen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
19/11	Biosergen publishes interim report for the third quarter 2025
28/10/25	Biosergen's Nomination Committee appointed
22/09/25	ECDC sounds alarm on C. auris – Biosergen eyes role in containment
17/09/25	Mrkt BUZZ, Biosergen: Candidozyma auris on the rise in Europe
02/09/25	Research update Biosergen: Ongoing development going according to plan
21/08/25	Biosergen’s CEO on the preparations for the next clinical phase
20/08/25	Biosergen AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
20/08/25	Biosergen publishes its interim report for the second quarter 2025
25/07/25	Biosergen strengthens executive team amid clinical momentum
24/07/25	Biosergen Names New CFO
24/07/25	Biosergen appoints Mark Beveridge as CFO
24/07/25	Biosergen Appoints Mark Beveridge as Chief Financial Officer
24/07/25	Biosergen AB Announces Chief Financial Officer Changes
11/06/25	Biosergen AB Elects Marco Taglietti as Member of the Board of Directors and Establishes Nomination Committee